Respirerx Pharmaceuticals Inc., of Glen Rock, N.J., said data are being presented at the Experimental Biology Conference in San Diego describing the use of ampakines to overcome opioid-induced respiratory depression. Data also showed that ampakines can significantly improve respiratory function after spinal cord injury and that ampakines can boost the efficacy of an emerging therapy using intermittent hypoxia that strengthens the motor control of patients after spinal cord injury.